Entity

Time filter

Source Type

Le Locle, Switzerland

Noone C.,National University of Ireland, Maynooth | Kihm A.,A Johnson And Johnson Company | English K.,National University of Ireland, Maynooth | O'Dea S.,National University of Ireland, Maynooth | Mahon B.P.,National University of Ireland, Maynooth
Stem Cells and Development | Year: 2013

Umbilical cord tissue represents a unique source of cells with potential for cell therapy applications for multiple diseases. Human umbilical tissue-derived cells (hUTC) are a developmentally early stage, homogenous population of cells that are HLA-ABC dim, HLA-DR negative, and lack expression of co-stimulatory molecules in the unactivated state. The lack of HLA-DR and co-stimulatory molecule expression on unactivated hUTC may account for their reduced immunogenicity, facilitating their use in allogeneic settings. However, such approaches could be confounded by host innate cells such as natural killer (NK) cells. Here, we evaluate in vitro NK cell interactions with hUTC and compare them with human mesenchymal stem cells (MSC). Our investigations show that hUTC suppress NK activation, through prostaglandin-E2 secretion in a contact-independent manner. Prestimulation of hUTC or human MSC with interferon gamma (IFN-γ) induced expression of the tryptophan degrading enzyme indoleamine 2, 3 dioxygenase, facilitating enhanced suppression. However, resting NK cells of different killer immunoglobulin-like receptor haplotypes did not kill hUTC or MSC; only activated NK cells had the ability to kill nonstimulated hUTC and, to a lesser extent, MSC. The cell killing process involved signaling through the NKG2D receptor and the perforin/granzyme pathway; this was supported by CD54 (ICAM-1) expression by hUTC. IFN-γ-stimulated hUTC or hMSC were less susceptible to NK killing; in this case, protection was associated with elevated HLA-ABC expression. These data delineate the different mechanisms in a two-way interaction between NK cells and two distinct cell therapies, hUTC or hMSC, and how these interactions may influence their clinical applications. © Copyright 2013, Mary Ann Liebert, Inc. 2013. Source


Shellock F.G.,University of Southern California | Bedwinek A.,A Johnson And Johnson Company | Oliver-Allen M.,Loyola Marymount University | Wilson S.F.,A Johnson And Johnson Company
American Journal of Roentgenology | Year: 2011

OBJECTIVE. A newly developed CSF shunt valve that incorporates a magnetically adjustable mechanism designed to resist unintended setting changes was evaluated for problems during 3-T MRI. MATERIALS AND METHODS. Standardized protocols were used to assess magnetic field interactions, MRI-related heating, artifacts, and functional changes related to multiple exposures and various MRI conditions in nine different samples at 3 T. RESULTS. The magnetic field interactions were not excessive. MRI-related heating, which was studied at a relatively high, MRI system-reported whole body-averaged specific absorption rate (2.9 W/kg), was at a level that should not pose a hazard to a patient. Although artifacts were large in relation to the dimensions of this programmable CSF shunt valve, the results were consistent with similar devices containing permanent magnets. Multiple exposures and various MRI conditions at 3 T did not damage or affect the functional aspects of the devices, and no unintentional changes to the valve setting were observed. CONCLUSION. In consideration of the test results, this new programmable CSF shunt valve is not adversely affected by the 3-T MRI environment and is acceptable for a patient undergoing MRI at 3 T or less when specific guidelines are followed, including verifying the valve setting according to manufacturer recommendations immediately after the MRI procedure. © American Roentgen Ray Society. Source


Serruys P.W.,Erasmus Medical Center | Onuma Y.,Erasmus Medical Center | Garg S.,Erasmus Medical Center | Vranckx P.,Hartcentrum | And 11 more authors.
Journal of the American College of Cardiology | Year: 2010

Objectives: The purpose of this study is to compare the 5-year clinical outcomes, safety, and efficacy of sirolimus-eluting stents (SES) in the ARTS II (Arterial Revascularization Therapies Study II) with the outcomes of coronary artery bypass graft (CABG) and bare-metal stenting (BMS) from the ARTS I. Background: The long-term outcomes after SES implantation in patients with multivessel disease remains to be established. Methods: The ARTS I was a randomized trial of 1,205 patients with multivessel disease comparing CABG and BMS. The ARTS II study was a nonrandomized trial with the Cypher sirolimus-eluting stent (Cordis, a Johnson & Johnson Company, Warren, New Jersey), applying the same inclusion and exclusion criteria, end points, and protocol definitions. The ARTS II trial enrolled 607 patients, with an attempt to enroll at least one-third of patients with 3-vessel disease. Results: At 5-year, the death/stroke/myocardial infarction event-free survival rate was 87.1% in ARTS II SES, versus 86.0% (p = 0.1) and 81.9% (p = 0.007) in ARTS I CABG and BMS cohorts, respectively. The 5-year major adverse cardiac and cerebrovascular event (MACCE) rate in ARTS II (27.5%) was significantly higher than ARTS I CABG (21.1%, p = 0.02), and lower than in ARTS I BMS (41.5%, p < 0.001). The cumulative incidence of definite stent thrombosis was 3.8%. Thirty-two percent (56 of 176) of major adverse cardiac events (MACE) at 5 years were related to possible, probable, or definite stent thrombosis. Conclusions: At 5 years, SES had a safety record comparable to CABG and superior to BMS, and a MACCE rate that was higher than in patients treated with CABG, and lower than in those treated with BMS. Approximately one-third of the events seen with SES could be prevented through the elimination of early, late, and very late stent thrombosis. © 2010 American College of Cardiology Foundation. Source


Andjelic S.,A Johnson And Johnson Company | Scogna R.C.,A Johnson And Johnson Company
Journal of Applied Polymer Science | Year: 2015

The intention of this study is to discuss scientific advances toward one very important challenge in the polymer processing industry: How does one increase the crystallization rate of slow-to-crystallize polymeric materials, thereby facilitating processing and enabling peak product performance? In the medical device field, where both government-controlled regulatory entities and medical professionals closely scrutinize the biocompatibility of added crystallization rate enhancers, achieving these twin goals has always been challenging. Herein, we present a review of various chemical and physical approaches used to tune the crystallization rate of semicrystalline polymers, with a strong emphasis on two novel approaches recently discovered and developed in our laboratories. © 2015 Wiley Periodicals, Inc. Source


Friedrich F.,Ecole Polytechnique Federale de Lausanne | Friedrich F.,A Johnson And Johnson Company | Lockhart R.,Ecole Polytechnique Federale de Lausanne | Briand D.,Ecole Polytechnique Federale de Lausanne | And 9 more authors.
IEEE International Ultrasonics Symposium, IUS | Year: 2012

This work presents a light and powerful silicon based ultrasonic micro-cutter. In order to achieve high cutting efficiency as well as good controllability when driven by commercially available control systems, important design parameters haven been identified. They have been verified by FEM-simulation as well as experiments via laser Doppler vibrometer measurements and cutting tests. The samples have been manufactured cost-effectively by microfabrication batch processing and their cutting ability has been successfully demonstrated on chicken tissue, while driven in a typical frequency range from 50 kHz to 100 kHz, generating tip displacements up to 36 μmpp. © 2012 IEEE. Source

Discover hidden collaborations